These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 24216259)

  • 1. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
    Adema AY; de Borst MH; Ter Wee PM; Vervloet MG;
    J Ren Nutr; 2014 May; 24(3):143-50. PubMed ID: 24216259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG; Elisaf MS
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
    Rastogi A
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB; Martin KJ
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of phosphate binders in moderate CKD.
    Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
    J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Hanba Y; Masumoto A; Moribata M; Shigemathu T
    Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial.
    Sigrist M; Tang M; Beaulieu M; Espino-Hernandez G; Er L; Djurdjev O; Levin A
    Nephrol Dial Transplant; 2013 Jan; 28(1):161-9. PubMed ID: 23024219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Information about phosphorus additives and nutritional counseling].
    Kido S; Nomura K; Sasaki S; Shiozaki Y; Segawa H; Tatsumi S
    Clin Calcium; 2012 Oct; 22(10):1583-91. PubMed ID: 23023640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake.
    Uribarri J
    Semin Dial; 2007; 20(4):295-301. PubMed ID: 17635818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
    Yilmaz MI; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Mallamaci F; Zoccali C
    Am J Kidney Dis; 2012 Feb; 59(2):177-85. PubMed ID: 22137672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic interventions for chronic kidney disease-mineral and bone disorders: focus on mortality.
    Block GA
    Curr Opin Nephrol Hypertens; 2011 Jul; 20(4):376-81. PubMed ID: 21519253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].
    Mukhin NA; Milovanov YS; Kozlovskaya LV; Dobrosmyslov IA; Milovanova LY
    Ter Arkh; 2016; 88(4):41-45. PubMed ID: 27070162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
    Larsson T; Nisbeth U; Ljunggren O; Jüppner H; Jonsson KB
    Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.